Nav: Home

Protection for the gut barrier: New approach may prevent graft-versus-host disease

April 20, 2017

Stem cell transplants can save lives, for example in patients with leukemia. However, these treatments are not free of risks. One complication that may occur is graft-versus-host disease (GVHD), basically donor-derived immune cells attacking the recipient's body. A team at the Technical University of Munich (TUM) has identified molecular mechanisms that may protect patients against this dangerous response in the future. The key to preventing GVHD is in the gut.

In order to enable foreign stem cells to multiply in the body and produce healthy blood cells, doctors first need to make room for them. This is achieved by destroying existing cells in the bone marrow using drugs or radiation.

One of the risks resulting from this pre-treatment is GVHD, which occurs in about half of all treatments. In simple terms, during GVHD the transplanted stem cells become T lymphocytes. These immune cells, which are supposed to fight intruders such as bacteria, take a wrong turn and start attacking the recipient's already weakened body.

In a paper published in the journal Science Translational Medicine, an international team headed by TUM adjunct teaching professor Dr. Hendrik Poeck and Dr. Tobias Haas, heads of a research group at the third medical clinic of TUM's Klinikum rechts der Isar, and Professor Marcel van den Brink at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City, describes how this process could be prevented.

Triggered in the gut

The attacks by the T cells primarily affect the skin, liver and in particular the gastrointestinal tract. The intestine is believed to be the key organ where GVHD starts. The drug treatment and radiation cause damage to the epithelial cells, which form part of the intestinal mucosal layer. Stress signals emitted by the dying epithelial cells and the arrival of intestinal bacteria in the previously germ-free areas of the gut due to the loss of the epithelium trigger a sort of red alert that activates aggressive donor T cells. "If the epithelium could be protected or quickly restored, the risk of an immune response would be much lower," says Hendrik Poeck. "Up to now, however, there have been very few treatment strategies that seek to regenerate the epithelium."

The scientists working with Dr. Poeck studied two proteins produced naturally in the body and known for their role in fighting bacteria and viruses: RIG-I and STING. "We were able to demonstrate for the first time that both of them can also be used to bring about a regenerative effect," says Julius Fischer, first author of the study. Both proteins are part of signal chains that cause type I interferon (IFN-I) to be produced. IFN-I triggers many different immune responses, but can also speed up the replacement of epithelial cells.

Timing is key

It is well established that the RIG-I signal pathway can be deliberately stimulated using triphosphate-RNA (3pRNA). Poeck and his team were able to demonstrate in mice that 3pRNA can indeed protect the epithelial cells. The timing is decisive: Measurable protection was only seen when the 3pRNA was administered exactly one day before the start of radiation and drug treatment. "We assume that after just one day of treatment, there would no longer be enough intact epithelial cells in the gut for the RIG-I/IFN signal path to function," explains Tobias Haas. Although fewer activated T cells were generated after a treatment with 3pRNA, the positive effect of the leukemia therapy was not reduced to a measurable degree.

"Both RIG-I agonists, such as 3pRNA, and STING agonists are currently in clinical development," says Hendrik Poeck. The research points to a wide range of potential applications, especially in the treatment of tumors. "Our study shows that regenerative processes can also be triggered through selective activation of these signal paths," adds Poeck, explaining his team's results. "It thus appears quite possible that these selective agonists will be administered in the future to patients who are candidates for allogeneic stem cell transplants. However, further studies will be needed to learn how they actually work before applications in human medicine are possible."
-end-
Publication:

J. C. Fischer, M. Bscheider, G. Eisenkolb, C.-C. Lin, A. Wintges, V. Otten, C. A. Lindemans, S. Heidegger, M. Rudelius, S. Monette, K. A. Porosnicu Rodriguez, M. Calafiore, S. Liebermann, C. Liu, S. Lienenklaus, S. Weiss, U. Kalinke, J. Ruland, C. Peschel, Y. Shono, M. Docampo, E. Velardi, R. Jenq, A. M. Hanash, J. A. Dudakov, T. Haas, M. R.M. van den Brink and H. Poeck. "RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury". Science Translational Medicine (2017). 9:386. DOI: 10.1126/scitranslmed.aag2513

Further Information:

The research group's website: http://www.med3.med.tum.de/forschung/Grundlagenforschung/Tumorimmunologie/haaspoeck.html

High-resolution images:

https://mediatum.ub.tum.de/1356990

Contact:

PD Dr. med. Hendrik Poeck
Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie
Klinikum Rechts der Isar
Technische Universität München
Tel: +49 (0) 89 4140 8065
Email: hendrik.poeck@tum.de

Technical University of Munich (TUM)

Related Immune Cells Articles:

How an immune system regulator shifts the balance of immune cells
Researchers have provided new insight on the role of cyclic AMP (cAMP) in regulating the immune response.
How the immune system becomes blind to cancer cells
Researchers have described the activation of a key protein used by tumor cells to stop the body's immune response.
What protects killer immune cells from harming themselves?
White blood cells, which release a toxic potion of proteins to kill cancerous and virus-infected cells, are protected from any harm by the physical properties of their cell envelopes, find scientists from UCL and the Peter MacCallum Cancer Centre in Melbourne.
How self-reactive immune cells are allowed to develop
A research team at Lund University in Sweden has found the mechanism that controls the growth of B1-cells in mice.
Identification of new populations of immune cells in the lungs
In an article published in Nature Communications, the Immunophysiology Laboratory of the GIGA Institute, headed by Prof.
A genomic barcode tracker for immune cells
A new research method to pinpoint the immune cells that recognise cancer could significantly change how we treat the disease.
Scientists reminded immune cells on what side they should be
International group of scientists in the joint study of the laboratory of the Wistar Institute, University of Pittsburgh and I.M.
Dead cells disrupt how immune cells respond to wounds and patrol for infection
Immune cells prioritise the clearance of dead cells overriding their normal migration to sites of injury.
Study gives new perspective on production of blood cells and immune cells
A new study provides a thorough accounting of blood cell production from hematopoietic stem cells.
Gut immune cells play by their own rules
Only a few vaccines -- for example, against polio and rotavirus -- can be given orally.
More Immune Cells News and Immune Cells Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Uncharted
There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#555 Coronavirus
It's everywhere, and it felt disingenuous for us here at Science for the People to avoid it, so here is our episode on Coronavirus. It's ok to give this one a skip if this isn't what you want to listen to right now. Check out the links below for other great podcasts mentioned in the intro. Host Rachelle Saunders gets us up to date on what the Coronavirus is, how it spreads, and what we know and don't know with Dr Jason Kindrachuk, Assistant Professor in the Department of Medical Microbiology and infectious diseases at the University of Manitoba. And...
Now Playing: Radiolab

Dispatch 1: Numbers
In a recent Radiolab group huddle, with coronavirus unraveling around us, the team found themselves grappling with all the numbers connected to COVID-19. Our new found 6 foot bubbles of personal space. Three percent mortality rate (or 1, or 2, or 4). 7,000 cases (now, much much more). So in the wake of that meeting, we reflect on the onslaught of numbers - what they reveal, and what they hide.  Support Radiolab today at Radiolab.org/donate.